R
Robert M. Merion
Researcher at University of Michigan
Publications - 301
Citations - 28862
Robert M. Merion is an academic researcher from University of Michigan. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 81, co-authored 297 publications receiving 26529 citations. Previous affiliations of Robert M. Merion include Eli Lilly and Company & University of Pennsylvania.
Papers
More filters
Journal Article
Survival benefit of kidney and liver transplantation for obese patients on the waiting list.
Shawn J. Pelletier,Martin A. Maraschio,Douglas E. Schaubel,Dawn M. Dykstra,Jeffrey D. Punch,Robert A. Wolfe,Friedrich K. Port,Robert M. Merion +7 more
TL;DR: It is demonstrated that kidney transplantation offers a significant survival benefit and is the preferred therapy for most obese dialysis patients, and obesity should not be a contraindication for transplantation.
Journal ArticleDOI
Transplants in Foreign Countries Among Patients Removed from the US Transplant Waiting List.
Robert M. Merion,A. D. Barnes,Monica Jia-Yeong Lin,Valarie B. Ashby,V. McBride,E. Ortiz-Rios,J. C. Welch,Gregory N. Levine,Friedrich K. Port,J. Burdick +9 more
TL;DR: Transplant tourism, where patients travel to foreign countries specifically to receive a transplant, is poorly characterized and the full extent of this practice cannot be determined using existing data.
Journal ArticleDOI
Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.
Pescovitz,David J. Conti,J. Dunn,Thomas A. Gonwa,Philip F. Halloran,Hans W. Sollinger,Stephen J. Tomlanovich,S. Weinstein,S. Inokuchi,Bryce A. Kiberd,Dilip S. Kittur,Robert M. Merion,Douglas J. Norman,Ahmed Shoker,R. Wilburn,Andrew J. Nicholls,S. Arterburn,E. Dumont +17 more
TL;DR: The intravenous formulation of mycophenolate mofetil should provide efficacy at least equivalent to p.o.v. MMF without increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.
Journal ArticleDOI
Variation in access to the liver transplant waiting list in the United States.
Amit K. Mathur,Valarie B. Ashby,Douglas S. Fuller,Min Zhang,Robert M. Merion,Alan B. Leichtman,John D. Kalbfleisch +6 more
TL;DR: The marked inequity in early access to liver transplantation underscores the need for local and national policy initiatives to affect this disparity.
Journal ArticleDOI
Histologic progression of recurrent hepatitis C in liver transplant allografts.
TL;DR: Recurrent HCV appears to progress from an acute lobular hepatitis to chronic hepatitis with lymphoid aggregates in the majority of patients, and the long-term course of recurrent HCV in liver allografts may not be as indolent as first thought.